Toggle Nav
My Cart
Search
Advanced Search
Menu
Account
Settings

Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028

Healthcare Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028

Collaborations with Innovative Platform Developers will Drive Growth Potential

INDUSTRY
Healthcare

RELEASE DATE
17-Jul-2023
REGION
Global
DELIVERABLE TYPE
Market Research

RESEARCH CODE
PED8-01-00-00-00
SKU
TEMP_2023_8
Yes
SHARE

$2,450.00

Special Price $1,837.50 save 25 %

In stock
SKU
TEMP_2023_8

Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028
Published on: 17-Jul-2023 | SKU: TEMP_2023_8

Need more details?

$2,450.00

$1,837.50 save 25 %

Request Sample
Need more details?
Description

This research service overviews the global ADC market and provides a 6-year revenue forecast from 2023 to 2028. An ADC comprises multiple components such as the antibody, conjugation chemistry, linker, and payload. Many companies are working on each component while others only develop ADCs, which makes the market highly competitive. The development of targeted delivery vehicles over standard antibodies is improving the performance of these drugs and expanding their potential for treating new cancers. New technologies are trying to address drawbacks of existing ADC technology, such as poor stability, leading to poor tolerability, efficacy, and a narrow therapeutic index and challenging ADC manufacturing.

Frost & Sullivan’s analysis shows that small and mid-sized enterprises that rely on contract development and manufacturing organizations (CDMOs)/contract research organizations (CROs) for initial drug development create novel antibody therapeutic technologies. Many antibody developers have been decreasing in-house R&D efforts and increasing in-licensing or acquiring therapeutic antibody product lines to strengthen their pipelines. All major CDMOs are stepping up with new investments to support the next generation of ADC, making the segment more competitive. Biopharmaceutical companies are focusing on ADCs to reap the benefits of target specificity for selective tumor antigens. Developers are using robust approaches to improve payloads’ potency as ADCs reflect the success rate in the last two years with seven approvals.

Other information included in the report consists of the following:
• Market trends
• Leading disruptors
• Marketed and pipeline ADC that will drive growth in hematological and solid tumors
• Growth opportunities emerging from this space that stakeholders can leverage

Author: Surbhi Gupta

Table of Contents

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the ADC Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

ADC Market Highlights

Growth Opportunities: The ADC Market

Growth Drivers

Growth Restraints

Drug Conjugates’ History, Progress, and Research Stages

ADC Market Trends

ADC Technology Evolution

Precision Oncology Approaches for ADCs

Biomarker Application Across the Cancer Continuum

Life Cycle Management Strategies

ADC Deals and Investment Outlook

Notable ADC Partnerships and Collaborations, 2022

Notable ADC Partnerships and Collaborations, 2022 (continued)

Notable ADC Partnerships and Collaborations, 2022 and 2023

Approved ADCs: Hematological Cancer

Approved ADCs: Solid Tumors

Late-stage ADCs to Watch

Forecast Assumptions

Growth Metrics

Revenue Forecast

Revenue Forecast Analysis: Solid Tumors (Launched)

Revenue Forecast Analysis: Solid Tumors (Launched) (continued)

Revenue Forecast Analysis: Solid Tumors (Launched) (continued)

Revenue Forecast Analysis: Solid Tumors (Pipeline)

Revenue Forecast Analysis: Hematological Cancer (Launched)

Revenue Forecast Analysis: Hematological Cancer (Launched) (continued)

Revenue Forecast Analysis: Hematological Cancer (Late-stage Pipeline)

Tubulis: Broad Spectrum of Technology Platforms

LCB: Conjugation Technology Platforms

Synaffix (Lonza): End-to-end ADC Services

WuXi Biologics: ADC CRDMO

Mersana Therapeutics: Late-stage ADC Pipeline and Platform

Iksuda: A Toolbox Approach for ADC Development

Growth Opportunity 1: ADC Combination Therapies for Precision Chemotherapeutics

Growth Opportunity 1: ADC Combination Therapies for Precision Chemotherapeutics (continued)

Growth Opportunity 2: Strategic Partnerships between CDMOs and Early-stage Platform and ADC Developers

Growth Opportunity 2: Strategic Partnerships between CDMOs and Early-stage Platform and ADC Developers (continued)

Growth Opportunity 3: Novel Linkers and Conjugation Chemistries

Growth Opportunity 3: Novel Linkers and Conjugation Chemistries (continued)

List of Exhibits

Legal Disclaimer

List of Figures & Charts
List of Figures
  • ADCs: Growth Drivers, Global, 2023-2028
  • ADCs: Growth Restraints, Global, 2023-2028
  • ADCs: Growth Metrics, Global, 2022
  • ADCs: Revenue Forecast, Global, 2021-2028
Request Sample

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

06 Aug 2026   |   Global   |   Technology Research

Decentralized Clinical Trials Powered by Blockchain and Digital Twins

This report examines how decentralized clinical trials (DCTs), enabled by blockchain, digital twins, and artificial intelligence, are reshaping global clinical research. It traces the shift from site-centric to patient-centric models and quantifies the growing scale, globalization, and complexity of...

04 Aug 2026   |   Global   |   Market Research

Global Capnography Devices Market, Forecast to 2031

The capnography market is undergoing a significant transformation from its traditional role in anesthesia and intensive care monitoring to a broader, continuous respiratory surveillance ecosystem. This evolution is being driven by increasing integration of capnography into multiparameter monitoring ...

31 Jul 2026   |   Global   |   Market Research

Growth Opportunities in Small-Molecule Contract Development and Manufacturing Organizations, Global, 2026–2031

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward s...

30 Jul 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Wearables and Drug Delivery Solutions

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, wearables and drug delivery solutions.

The issue features advanced medical devices such as non-invasive bimoda...

30 Jul 2026   |   Global   |   Frost Radar

Frost Radar™: Life Sciences Regulatory Information Management Platforms, 2026

The regulatory technology market in life sciences has, over the last five years, quietly transformed from a back-office category dominated by document repositories and submission publishing tools to one of the most consequential software segments serving the pharmaceutical, biotech, and medical devi...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts
Related Research
  1. Frost Radar™: Antibody-Drug Conjugate Contract Development and Manufacturing Organizations, 2025
    Release Date: 02-Dec-25
  2. Antibody-drug Conjugates: Technology Growth Opportunities
    Release Date: 21-Dec-22
  3. Growth Opportunities in Global Pharmaceutical Industry, 2026
    Release Date: 17-Mar-26
  4. Innovations and Growth Opportunities in AI-Driven Drug Discovery, Precision Diagnostics, Advanced Biologics, and Next-generation Vaccines
    Release Date: 17-Jul-26
  5. Innovations and Growth Opportunities in AI-Driven Drug Discovery, Protein Engineering, Genomic Diagnostics, Advanced Drug Delivery, and Precision Medicine
    Release Date: 19-Jun-26

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

This research service overviews the global ADC market and provides a 6-year revenue forecast from 2023 to 2028. An ADC comprises multiple components such as the antibody, conjugation chemistry, linker, and payload. Many companies are working on each component while others only develop ADCs, which makes the market highly competitive. The development of targeted delivery vehicles over standard antibodies is improving the performance of these drugs and expanding their potential for treating new cancers. New technologies are trying to address drawbacks of existing ADC technology, such as poor stability, leading to poor tolerability, efficacy, and a narrow therapeutic index and challenging ADC manufacturing. Frost & Sullivan’s analysis shows that small and mid-sized enterprises that rely on contract development and manufacturing organizations (CDMOs)/contract research organizations (CROs) for initial drug development create novel antibody therapeutic technologies. Many antibody developers have been decreasing in-house R&D efforts and increasing in-licensing or acquiring therapeutic antibody product lines to strengthen their pipelines. All major CDMOs are stepping up with new investments to support the next generation of ADC, making the segment more competitive. Biopharmaceutical companies are focusing on ADCs to reap the benefits of target specificity for selective tumor antigens. Developers are using robust approaches to improve payloads’ potency as ADCs reflect the success rate in the last two years with seven approvals. Other information included in the report consists of the following: • Market trends • Leading disruptors • Marketed and pipeline ADC that will drive growth in hematological and solid tumors • Growth opportunities emerging from this space that stakeholders can leverage Author: Surbhi Gupta
More Information
Deliverable Type Market Research
Author Surbhi Gupta
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Antibody Drug Conjugate
Keyword 2 Adc Drug
Keyword 3 Drug Conjugate
List of Charts and Figures ADCs: Growth Drivers, Global, 2023-2028~ ADCs: Growth Restraints, Global, 2023-2028~ ADCs: Growth Metrics, Global, 2022~ ADCs: Revenue Forecast, Global, 2021-2028~
Podcast No
WIP Number PED8-01-00-00-00